• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

不同KRAS基因亚型的结直肠癌免疫微环境分析

Analysis of the immune microenvironment in colorectal cancer with different KRAS gene subtypes.

作者信息

Huang Jing, Gong Qian, Li Qingshu, Xiao Ming, Li Ming, Zhang Shuxian, Wang Yalan, Tang Yi

机构信息

Department of Pathology, College of Basic Medicine, Chongqing Medical University, Chongqing, 400016, China.

Molecular Medicine Diagnostic and Testing Center, Chongqing Medical University, Chongqing, 400016, China.

出版信息

BMC Cancer. 2025 Aug 4;25(1):1267. doi: 10.1186/s12885-025-14660-5.

DOI:10.1186/s12885-025-14660-5
PMID:40759935
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12323061/
Abstract

BACKGROUND

To explore the differences in tumor immune microenvironment between different KRAS mutation subtypes, and to provide a new direction for clinical immunotherapy of different subtypes of colorectal cancer.

METHODS

We examined the spatial distribution of common inflammatory cell markers of CD8 + T cells, CD4 + T cells, natural killer cells, and B cells and macrophages in 55 colorectal cancer patients with different KRAS gene phenotypes using immunohistochemistry and panoramic scanning. We analyzed the relationship between inflammatory cells and clinical information. TCGA and String online databases were used to analyze the relationship between KRAS mutation subtypes and inflammatory cell markers.

RESULTS

We observed that significant differences in the spatial distribution of the tumor invasion front and the immune cell infiltration within the tumor. Colorectal cancer patients with different KRAS mutations showed different immune infiltration, and the main cells with differences were FOXP3 regulatory T cells and M2 macrophages. Furthermore, these two cell types were strongly associated with the prognosis of KRAS wild-type and KRAS mutant colorectal cancer.

CONCLUSIONS

The complexity of the immune microenvironment cannot be explained by infiltration of specific cell types alone, but may arise from cell-to-cell interactions or changes in the proportion of different immune cells. However, the infiltration of FOXP3 cells and M2 macrophages probably accounts for the differences between KRAS mutant subtypes.

摘要

背景

探讨不同KRAS突变亚型之间肿瘤免疫微环境的差异,为不同亚型结直肠癌的临床免疫治疗提供新方向。

方法

我们采用免疫组织化学和全景扫描技术,检测了55例具有不同KRAS基因表型的结直肠癌患者中CD8 + T细胞、CD4 + T细胞、自然杀伤细胞、B细胞和巨噬细胞等常见炎性细胞标志物的空间分布。我们分析了炎性细胞与临床信息之间的关系。利用TCGA和String在线数据库分析KRAS突变亚型与炎性细胞标志物之间的关系。

结果

我们观察到肿瘤侵袭前沿的空间分布以及肿瘤内免疫细胞浸润存在显著差异。不同KRAS突变的结直肠癌患者表现出不同的免疫浸润,主要存在差异的细胞是FOXP3调节性T细胞和M2巨噬细胞。此外,这两种细胞类型与KRAS野生型和KRAS突变型结直肠癌的预后密切相关。

结论

免疫微环境的复杂性不能仅用特定细胞类型的浸润来解释,而可能源于细胞间相互作用或不同免疫细胞比例的变化。然而,FOXP3细胞和M2巨噬细胞的浸润可能是KRAS突变亚型之间差异的原因。

相似文献

1
Analysis of the immune microenvironment in colorectal cancer with different KRAS gene subtypes.不同KRAS基因亚型的结直肠癌免疫微环境分析
BMC Cancer. 2025 Aug 4;25(1):1267. doi: 10.1186/s12885-025-14660-5.
2
Identification and validation of a KRAS-macrophage-associated gene signature as prognostic biomarkers and potential therapeutic targets in melanoma.鉴定和验证一种与KRAS-巨噬细胞相关的基因特征作为黑色素瘤的预后生物标志物和潜在治疗靶点。
Front Immunol. 2025 Jun 18;16:1566432. doi: 10.3389/fimmu.2025.1566432. eCollection 2025.
3
Exploring the role of monocarboxylate transporter 4 in diverse KRAS mutation subtypes of colorectal Cancer.探索单羧酸转运蛋白4在结直肠癌不同KRAS突变亚型中的作用。
Sci Rep. 2025 Jul 2;15(1):23257. doi: 10.1038/s41598-025-06254-9.
4
Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.用于转移性结直肠癌的表皮生长因子受体(EGFR)抑制剂
Cochrane Database Syst Rev. 2017 Jun 27;6(6):CD007047. doi: 10.1002/14651858.CD007047.pub2.
5
KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis.成人转移性结直肠癌肿瘤的KRAS突变检测:一项系统评价与成本效益分析
Health Technol Assess. 2014 Oct;18(62):1-132. doi: 10.3310/hta18620.
6
KRAS amplification in colorectal cancer: correlations with clinicopathological features and prognosis in patients and prediction of response to targeted therapy.结直肠癌中KRAS基因扩增:与患者临床病理特征及预后的相关性以及对靶向治疗反应的预测
J Transl Med. 2025 Jul 24;23(1):824. doi: 10.1186/s12967-025-06864-x.
7
Computational pathology applied to clinical colorectal cancer cohorts identifies immune and endothelial cell spatial patterns predictive of outcome.应用于临床结直肠癌队列的计算病理学可识别预测预后的免疫和内皮细胞空间模式。
J Pathol. 2025 Feb;265(2):198-210. doi: 10.1002/path.6378.
8
EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.表皮生长因子受体基因扩增和 PTEN 蛋白表达是 KRAS 野生型转移性结直肠癌患者接受西妥昔单抗治疗的有利预后因素。
J Cancer Res Clin Oncol. 2014 May;140(5):737-48. doi: 10.1007/s00432-014-1626-2. Epub 2014 Mar 5.
9
High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration.早期三阴性乳腺癌中肿瘤糖皮质激素受体的高表达与调节性T细胞浸润增加有关。
Breast Cancer Res Treat. 2025 Feb;209(3):563-572. doi: 10.1007/s10549-024-07515-3. Epub 2024 Nov 23.
10
Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.对难治性抗表皮生长因子受体(EGFR)治疗的结直肠癌患者循环肿瘤DNA中的克隆选择模式进行表征。
Ann Oncol. 2015 Apr;26(4):731-736. doi: 10.1093/annonc/mdv005. Epub 2015 Jan 26.

本文引用的文献

1
Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients with rare mutations: a real-world retrospective study.免疫检查点抑制剂在具有罕见突变的晚期非小细胞肺癌患者中的疗效:一项真实世界回顾性研究。
Transl Lung Cancer Res. 2024 Jul 30;13(7):1672-1684. doi: 10.21037/tlcr-24-372. Epub 2024 Jul 25.
2
Clinicopathological, molecular, and prognostic features of colorectal carcinomas with KRAS c.34G>T (p.G12C) mutation.结直肠癌中 KRAS c.34G>T(p.G12C)突变的临床病理、分子和预后特征。
Cancer Sci. 2024 Oct;115(10):3455-3465. doi: 10.1111/cas.16262. Epub 2024 Jul 22.
3
Spatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcome.
KRAS突变型非小细胞肺癌的空间iTME分析与免疫治疗结果
NPJ Precis Oncol. 2024 Jun 19;8(1):135. doi: 10.1038/s41698-024-00626-6.
4
Prognostic value of specific KRAS mutations in patients with colorectal peritoneal metastases.结直肠腹膜转移患者 KRAS 特定突变的预后价值。
ESMO Open. 2024 Apr;9(4):102976. doi: 10.1016/j.esmoop.2024.102976. Epub 2024 Apr 12.
5
Tumour-associated macrophage-derived DOCK7-enriched extracellular vesicles drive tumour metastasis in colorectal cancer via the RAC1/ABCA1 axis.肿瘤相关巨噬细胞衍生富含 DOCK7 的细胞外囊泡通过 RAC1/ABCA1 轴驱动结直肠癌转移。
Clin Transl Med. 2024 Feb;14(2):e1591. doi: 10.1002/ctm2.1591.
6
Evaluating distinct KRAS subtypes as potential biomarkers for immune checkpoint inhibitor efficacy in lung adenocarcinoma.评估不同 KRAS 亚型作为肺腺癌免疫检查点抑制剂疗效的潜在生物标志物。
Front Immunol. 2023 Oct 24;14:1297588. doi: 10.3389/fimmu.2023.1297588. eCollection 2023.
7
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.KRAS 密码子特异性突变预测转移性结直肠癌患者接受替氟尿苷/盐酸拓扑替康治疗的生存获益。
Nat Med. 2023 Mar;29(3):605-614. doi: 10.1038/s41591-023-02240-8. Epub 2023 Mar 2.
8
Colorectal cancer statistics, 2023.2023 年结直肠癌统计数据。
CA Cancer J Clin. 2023 May-Jun;73(3):233-254. doi: 10.3322/caac.21772. Epub 2023 Mar 1.
9
Metastatic colorectal cancer: mechanisms and emerging therapeutics.转移性结直肠癌:机制与新兴治疗策略。
Trends Pharmacol Sci. 2023 Apr;44(4):222-236. doi: 10.1016/j.tips.2023.01.003. Epub 2023 Feb 23.
10
Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases.原发灶三级淋巴结构的定位和密度与结直肠癌肝转移的分子亚型和临床结局相关。
J Immunother Cancer. 2023 Feb;11(2). doi: 10.1136/jitc-2022-006425.